Mark Faber
www.linkedin.com
0000-0003-4800-1216
Roswell Park Comprehensive Cancer Center
6 papers found
Refreshing results…
Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy
Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy
Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience
Predictors of vascular disease in myelodysplastic syndromes
Current State of Myelodysplastic Syndromes: Standard Treatment Practices and Therapeutic Advances
Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non–Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis
Missing publications? Search for publications with a matching author name.